Higly active Ansamitocin analogues for tumor therapy
The invention comprises designed novel biologically highly potent ansamitocin analogues for tumor therapy, inlcuding among other new 19-deschloro and demethoxy derivatives of known AP-3 ansamitocin, showing a strong inhibitory effect on cell growth. They could be the basis for a cancer therapy, and might show fewer side effects than the known ones tested at clinical studies.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-152
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Machine learning algorithm reveals long-theorized glass phase in crystal
Scientists have found evidence of an elusive, glassy phase of matter that emerges when a crystal’s perfect internal pattern is disrupted. X-ray technology and machine learning converge to shed light…
Mapping plant functional diversity from space
HKU ecologists revolutionize ecosystem monitoring with novel field-satellite integration. An international team of researchers, led by Professor Jin WU from the School of Biological Sciences at The University of Hong…
Inverters with constant full load capability
…enable an increase in the performance of electric drives. Overheating components significantly limit the performance of drivetrains in electric vehicles. Inverters in particular are subject to a high thermal load,…
